OPKO Health draws $125M against mazdutide royalties in KKR-linked deal
What's the deal? OPKO Health (Nasdaq: OPK) has raised $125 million in senior secured notes from HealthCare RoyaltyDealroom has a profile for this one. Try Dealroom →, a business of KKR & Co.Dealroom has a profile for this one. Try Dealroom →, in a post-IPO debt financing announced in August 2026. The notes are backed by OPKO's royalty rights under its mazdutide licence agreement with Eli LillyDealroom has a profile for this one. Try Dealroom →.
Why now? The financing expands an existing relationship with HealthCare Royalty and marks a step-up from OPKO's prior raise. It converts part of a future royalty stream into immediate, non-dilutive capital, avoiding the equity dilution a company with a low share price might otherwise face.
The context: Mazdutide is a dual glucagon and GLP-1 receptor agonist. Innovent Biologics commercialises it in China, giving OPKO exposure to one of pharma's most attractive categories, metabolic disease and GLP-1 therapies, without commercialising the drug itself.
By the numbers: OPKO ended the second quarter with $314.4 million in cash, cash equivalents, marketable securities and restricted cash. The new notes mature in 2044, consistent with existing HealthCare Royalty debt, and cap total payments at 1.5 times the funded amount, after which OPKO retains future royalty economics.
What's the endgame? The upfront capital gives management room to support research and development, buybacks, partnerships and commercial operations. OPK traded around $1.40 intraday on 13 August 2026, for a market capitalisation slightly above $1 billion.
What could go wrong? Non-dilutive financing is not free. OPKO is trading a portion of future mazdutide economics for cash today. If the drug becomes a large China franchise and OPKO deploys the capital productively, the deal could support the business; if not, shareholders may question monetising a valuable royalty stream.
The signal: The deal shows biotech and diagnostics firms increasingly borrowing against high-quality royalty assets rather than issuing equity, using GLP-1-linked cash flows to fund broader platforms while preserving long-term upside.
Image credit: foteih
Read more: Business News Today
